Hypercholesterolemia Clinical Trial
Official title:
A Double-Blind, Double-Dummy, Randomized, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 100 mg and Lapaquistat Acetate 100 mg Administered in Combination With Ezetimibe 10 mg vs Ezetimibe 10 mg in Subjects With Primary Dyslipidemia
The purpose of the study is to determine the efficacy of lapaquistat acetate, once daily (QD), taken with ezetimibe on cholesterol levels in subjects with primary dyslipidemia
Status | Completed |
Enrollment | 1267 |
Est. completion date | January 2007 |
Est. primary completion date | January 2007 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Females of childbearing potential who are sexually active must agree to use adequate contraception from screening throughout the duration of the study and for 30 days following the last dose. - Has a documented history of dyslipidemia with or without cardiovascular risk factors but without type 1 or 2 diabetes. - At Randomization, participants must fulfill the above criteria and also have a mean fasting low density lipoprotein cholesterol levels greater than or equal to 3.36 mmol/L and less than or equal to 5.6 mmol/L and mean triglyceride levels less than or equal to 4.52 mmol/L. - Is willing and able to comply with the recommended, standardized diet. Exclusion Criteria: - Has active liver disease or jaundice. - Has a history of cancer, other than basal cell carcinoma, that had been in remission for less than 5 years prior to the first dose of study drug. - Has an endocrine disorder, such as Cushing Syndrome, hyperthyroidism, or inappropriately treated hypothyroidism affecting lipid metabolism. - Has a positive hepatitis B surface antigen or hepatitis C virus antibody, as determined by medical history and/or the subject's verbal report. - Has a positive human immunodeficiency virus status or was taking antiretroviral medications, as determined by medical history and/or the subject's verbal report. . - Has participated in any other clinical studies with lapaquistat acetate, was concurrently participating in another investigational study, had participated in an investigational study within the past 30 days or, for drugs with a long half-life, within a period of less than 5 times the drug's half-life. - Has a known hypersensitivity or history of intolerance to lapaquistat acetate or ezetimibe. - Has a history or presence of clinically significant food allergy that would prevent adherence to the specialized diet. - Has a known heterozygous or homozygous familial hypercholesterolemia or known Type III hyperlipoproteinemia (familial dysbetalipoproteinemia). - Has fibromyalgia, myopathy, rhabdomyolysis, or unexplained muscle pain and/or discontinuation of HMG-CoA reductase inhibitors due to myalgia at any time. - Has uncontrolled hypertension despite medical treatment. - Has inflammatory bowel or any other malabsorption syndrome or had had gastric bypass surgery or any other surgical procedure for weight loss. - Has a history of drug abuse or a history of high alcohol intake within the previous 2 years. - Has any other serious disease or condition at Visit 1 or Randomization that might reduce life expectancy, impaired successful management according to the protocol, or make the participant unsuitable to receive study drug. - Has a history of coronary heart disease or coronary heart disease-risk factors comprised of: - Diabetes mellitus type 1 or 2 - History or presence of myocardial infarction, angina pectoris, unstable angina, coronary angioplasty, coronary or peripheral arterial surgery (bypass graft), aortic aneurysm, transient ischemic attacks, or cerebrovascular accident; - Multiple risk factors that confer a 10-year risk of coronary heart disease greater than 20% based on the Framingham risk score. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Takeda |
Estonia, Latvia, Russian Federation, Serbia,
Stein EA, Bays H, O'Brien D, Pedicano J, Piper E, Spezzi A. Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemia. Circulation. 2011 May 10;123(18):1974-85. doi: 10.1161/CIRCULATIONAHA.110.975284. Epub — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from Baseline in fasting plasma Low Density Lipoprotein cholesterol | Week 24 or Final Visit | No | |
Secondary | Change from Baseline in Triglycerides | Week 24 or Final Visit | No | |
Secondary | Change from Baseline in Total Cholesterol | Week 24 or Final Visit | No | |
Secondary | Change from Baseline in High Density Lipoprotein cholesterol | Week 24 or Final Visit | No | |
Secondary | Change from Baseline in Very Low Density Lipoprotein cholesterol | Week 24 or Final Visit | No | |
Secondary | Change from Baseline in apolipoprotein A1 | Week 24 or Final Visit | No | |
Secondary | Change from Baseline in apolipoprotein B | Week 24 or Final Visit | No | |
Secondary | Change from Baseline in non- High Density Lipoprotein cholesterol | Week 24 or Final Visit | No | |
Secondary | Change from Baseline in the ratio of Low Density Lipoprotein cholesterol/High Density Lipoprotein cholesterol | Week 24 or Final Visit | No | |
Secondary | Change from Baseline in the ratio of Total Cholesterol/High Density Lipoprotein cholesterol | Week 24 or Final Visit | No | |
Secondary | Change from Baseline in the ratio of apolipoprotein A1/apolipoprotein B | Week 24 or Final Visit | No | |
Secondary | Change from Baseline in high-sensitivity C-reactive protein | Week 24 or Final Visit | No | |
Secondary | Percentage of subjects who achieve Low Density Lipoprotein cholesterol concentrations less than 2.59 mmol/L (100 mg/dL) | Week 24 or Final Visit | No | |
Secondary | Percentage of subjects who achieve Low Density Lipoprotein cholesterol concentrations less than 3.37 mmol/L (130 mg/dL) | Week 24 or Final Visit | No | |
Secondary | Best corrected visual acuity | Week 24 or Final Visit | Yes | |
Secondary | Adverse Events | Weeks 2, 4, 8, 12, 16, 20, and 24 or Final Visit | Yes | |
Secondary | Clinical Laboratory Tests | Weeks 2, 4, 8, 12, 16, 20, and 24 or Final Visit | Yes | |
Secondary | Vital Signs | Weeks 2, 4, 8, 12, 16, 20, and 24 or Final Visit | Yes | |
Secondary | 12-lead Electrocardiogram | Weeks 12 and 24 or Final Visit | Yes | |
Secondary | Physical Examination | Week 24 or Final Visit | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Recruiting |
NCT03947866 -
Ezetimibe-Rosuvastatin Evaluation Study
|
||
Completed |
NCT01709513 -
Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)
|
Phase 3 | |
Completed |
NCT01212900 -
Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression
|
Phase 4 | |
Completed |
NCT00001154 -
Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
|
||
Completed |
NCT02550288 -
A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)
|
Phase 3 | |
Completed |
NCT03929198 -
Translation of Pritikin Program to the Community
|
N/A | |
Completed |
NCT04485793 -
Effect of a Dietary Supplement on Lipid Pattern and Liver Parameters in Hypercholesterolemia
|
N/A | |
Completed |
NCT02341924 -
Validating the "Foods for Health" Portfolio of Functional Food Products
|
N/A | |
Active, not recruiting |
NCT02223793 -
Vascular Lifestyle-Intervention and Screening in Pharmacy
|
N/A | |
Completed |
NCT01934608 -
The Effect of Synching Prescription Refills on Adherence
|
N/A | |
Completed |
NCT01941836 -
Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients
|
Phase 2 | |
Recruiting |
NCT01705873 -
Analysis on the Risk of Cardiovascular Events in HIV- Infected Subjects Treated With LPV/r Based HAART Regimen vs. an EFV Based Regimen
|
N/A | |
Completed |
NCT01678521 -
Effect of LDL-apheresis on PTX3 Plasma Levels in Hypercholesterolemic Patients
|
N/A | |
Completed |
NCT01670734 -
Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01370603 -
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)
|
Phase 3 | |
Completed |
NCT01370590 -
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)
|
Phase 3 | |
Completed |
NCT01478789 -
Efficacy of Plant Sterol-Fortified Dairy Product on Plasma Lipid and Plant Sterol Concentrations in Humans
|
N/A | |
Completed |
NCT01575171 -
Using Nudges to Implement Comparative Effectiveness
|
N/A | |
Completed |
NCT01446679 -
Special Drug Use-Results Survey of Lipitor Tablets
|
N/A |